Business context and reporting period
Filing identity differs from request metadata: the supplied filing is Kintara Therapeutics, Inc.’s Form 10-K for the fiscal year ended June 30, 2021, not a Tuhura Biosciences filing or a 2020 Q4 report. Kintara is a clinical-stage oncology company developing VAL-083 for glioblastoma and REM-001 for cutaneous metastatic breast cancer. It reported no revenue to date.
Financial results and liquidity
Amounts below are in US$ millions unless noted.
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $11.815 | $3.630 |
| General and administrative expense | $9.757 | $4.514 |
| Net loss | $38.298 | $9.126 |
| Net loss per share | $1.60 | $0.87 |
| Cash used in operating activities | $18.860 | $7.928 |
| Cash and cash equivalents at year-end | $10.537 | $2.392 |
| Working capital | $9.013 | $0.176 |
| Total assets | $13.543 | $2.938 |
| Total liabilities | $2.962 | $2.675 |
No operating margin is meaningful because the company reported no revenue. Net loss included a $16.094 million charge for acquired in-process research and development from the Adgero merger. Cash flow from investing activities was positive $0.964 million, mainly reflecting $0.969 million of cash acquired in that merger. Financing activities provided $26.041 million, including $21.598 million net proceeds from Series C preferred stock and $4.404 million from warrant exercises. The $0.500 million NBTS loan was repaid, with interest, in June 2021; no loan balance remained at year-end.
Material changes versus the prior period
- Net loss increased to $38.298 million from $9.126 million; R&D expense rose 225% and G&A expense rose 116%, reflecting expanded clinical development, the Adgero acquisition, personnel and share-based compensation.
- Operating cash use increased by $10.932 million to $18.860 million, including a $2.100 million increase in clinical-trial deposits.
- Year-end cash increased by $8.145 million, primarily due to preferred-stock financing and warrant exercises.
- The August 2020 Adgero merger added REM-001 and was treated as an asset acquisition; the acquired research and development asset was expensed because it had no alternative future use.
Outlook, risks and unusual items
- Going concern: the auditor’s report includes a going-concern explanatory paragraph; management and the auditor cite substantial doubt about the company’s ability to continue as a going concern. The company had an accumulated deficit of $111.225 million and said additional funding would be required.
- After year-end, a September 2021 registered direct offering raised approximately $15 million gross and $13.6 million net. Management estimated available cash would fund planned operations through Stage 1 of the GBM AGILE study, but stated that this was less than one year of runway from the financial statements’ issuance date and that further financing was needed.
- Management expected FY2022 R&D spending to exceed FY2021 levels as GBM AGILE continued and REM-001 development progressed. Planned milestones included potential GBM AGILE Stage 1 graduation in Q3 2022 and first REM-001 patient enrollment in Q2 2022; these were forward-looking targets, not assurances.
- Management reported positive topline results in completed VAL-083 Phase 2 studies, but comparisons were against historical controls, not randomized head-to-head results. The registrational GBM AGILE study was ongoing.
- Key risks include clinical and regulatory failure, dependence on additional capital and third-party manufacturers, potential dilution from preferred-stock conversion and warrants, and COVID-related manufacturing delays affecting REM-001. The filing says COVID-19 had not significantly disrupted GBM study enrollment or treatment to date.
- Series C preferred stock carries liquidation priority and stock dividends, creating potential dilution. The company also disclosed contingent REM-001 milestone payments of $0.3 million and $0.7 million and royalties on net sales under the St. Cloud agreement.
- The filing states disclosure controls and internal control over financial reporting were effective at June 30, 2021, and that a previously identified segregation-of-duties material weakness had been remediated. The auditor did not provide an opinion on internal control effectiveness.
Important facts for investors to verify
- Confirm the issuer and reporting period: the supplied document is Kintara’s FY2021 10-K, despite the Tuhura Biosciences and 2020 Q4 metadata.
- Review the going-concern disclosure and the actual cash runway, including subsequent financing proceeds, offering costs, and planned clinical-trial spending.
- Assess the clinical evidence and study designs behind VAL-083 topline results, and track GBM AGILE enrollment, safety, efficacy, and stage-transition decisions.
- Check REM-001 manufacturing readiness, FDA requirements, study timelines, and the company’s reliance on historical clinical data.
- Evaluate potential dilution from outstanding warrants, options, convertible Series C preferred stock and its stock dividends; confirm current share counts and terms after subsequent events.